About
Technology
Issues
FAQ
Links
Official Page
Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.